Enfusion Valuation
| ENFNDelisted Stock | USD 10.76 0.00 0.00% |
At this time, the firm appears to be overvalued. Enfusion shows a prevailing Real Value of $9.24 per share. The current price of the firm is $10.76. Our model computes the value of Enfusion from reviewing the firm fundamentals such as Shares Outstanding of 94.8 M, profit margin of 0.01 %, and Current Valuation of 1.01 B as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Enfusion's price fluctuation is very steady at this time. Calculation of the real value of Enfusion is based on 3 months time horizon. Increasing Enfusion's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Enfusion is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Enfusion Stock. However, Enfusion's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.76 | Real 9.24 | Hype 10.76 | Naive 10.79 |
The intrinsic value of Enfusion's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Enfusion's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Enfusion helps investors to forecast how Enfusion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enfusion more accurately as focusing exclusively on Enfusion's fundamentals will not take into account other important factors: Enfusion Total Value Analysis
Enfusion is currently forecasted to have valuation of 1.01 B with market capitalization of 1.02 B, debt of 20.31 M, and cash on hands of 56.56 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Enfusion fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.01 B | 1.02 B | 20.31 M | 56.56 M |
Enfusion Investor Information
About 96.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.35. Enfusion had not issued any dividends in recent years. Based on the analysis of Enfusion's profitability, liquidity, and operating efficiency, Enfusion is not in a good financial situation at the moment. It has a very high risk of going through financial straits in August.Enfusion Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Enfusion has an asset utilization ratio of 140.73 percent. This suggests that the Company is making $1.41 for each dollar of assets. An increasing asset utilization means that Enfusion is more efficient with each dollar of assets it utilizes for everyday operations.Enfusion Ownership Allocation
Enfusion holds a total of 94.8 Million outstanding shares. The majority of Enfusion outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Enfusion to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Enfusion. Please pay attention to any change in the institutional holdings of Enfusion as this could imply that something significant has changed or is about to change at the company. Also note that almost nine hundred twenty-nine thousand sixty-one invesors are currently shorting Enfusion expressing very little confidence in its future performance.Enfusion Profitability Analysis
The company reported the previous year's revenue of 201.61 M. Net Income was 3.92 M with profit before overhead, payroll, taxes, and interest of 136.74 M.About Enfusion Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Enfusion. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Enfusion based exclusively on its fundamental and basic technical indicators. By analyzing Enfusion's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Enfusion's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Enfusion. We calculate exposure to Enfusion's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Enfusion's related companies.Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois. Enfusion Inc operates under SoftwareApplication classification in the United States and is traded on New York Stock Exchange. It employs 892 people.
Enfusion Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 129.6 M | |
| Quarterly Earnings Growth Y O Y | -0.818 | |
| Forward Price Earnings | 47.619 |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Enfusion Stock
If you are still planning to invest in Enfusion check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Enfusion's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |